EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
European Commission approved Amgen's IMDYLLTRA for advanced small cell lung cancer based on Phase 3 DeLLphi-304 trial results showing 40% mortality risk reduction versus chemotherapy. The approval provides a new treatment option for patients with advanced disease.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
European Commission approval based on Phase 3 DeLLphi-304 trial demonstrating 40% reduction in mortality risk compared to chemotherapy
Importance:8/10
Sentiment:
0.85
regulatory approvalEuropean Commissionsmall cell lung cancerPhase 3 datamortality benefit
Related Companies
Read the original article
Published by PR Newswire Biotech on June 3, 2026 6:25 PM